ArticleBiomaterials research2023
Fe-curcumin nanozyme-mediated immunosuppression and anti-inflammation in experimental autoimmune uveitis.
Article in Biomaterials research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 29 citations in OpenAlex.
- Enhancing exosomes efficacy with engineered nanozymes for a multi-targeted combination strategy in osteoarthritis treatment.Materials today. Bio · 2026Article
- Synergistic osteogenesis, angiogenesis, and immune reprogramming by a metal-phenolic functionalized electrospun fibrous membrane for alveolar bone regeneration.Materials today. Bio · 2026Article
- Therapeutic potential of curcumin in ophthalmic diseases: mechanisms and clinical applications.Journal of translational medicine · 2025Review
- Recent advances in metallic nanostructure-based photothermal therapy in the management of cancer metastasis.Medical oncology (Northwood, London, England) · 2025Review
- Inorganic nanomaterials as promising therapeutic agents for ocular neovascularization: Progress and perspectives.Materials today. Bio · 2025Review
- Fe-curcumin nanozymes-mediated reactive oxygen species scavenging and anti-apoptotic effects on age-related cataracts.Materials today. Bio · 2025Article
- Advancements in herbal medicine-based nanozymes for biomedical applications.Chinese medical journal · 2025Review
- Nanozymes for Treating Ocular Diseases.Advanced healthcare materials · 2025Review
- Hydrogen Peroxide-Releasing Hydrogel-Mediated Cellular Senescence Model for Aging Research.Biomaterials research · 2025Article
- Enhanced ROS Production and Mitochondrial Metabolic Shifts in CD4International journal of molecular sciences · 2024Article
- Annexin-V binds subpopulation of immune cells altering its interpretation as anInternational journal of biological sciences · 2024Article
- Evaluation of the Ocular Safety of Hollow Mesoporous Organosilica Nanoparticles with Different Tetrasulfur Bond Content.International journal of nanomedicine · 2024Article
- Nano-based drug delivery systems for the treatment of non-infectious uveitis.Advances in ophthalmology practice and researchReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundEAU is an inflammatory disease usually characterized by autoinflammation and autoimmunity and is aggravated by excessive generation of ROS. Conventional hormone therapy often has more adverse effects. It is urgent to find a therapeutic drug with higher efficiency and fewer adverse effects.
methodsWe developed an Fe-curcumin nanozyme in which natural antioxidants coordinate with Fe
resultsFree radical scavenging experiments showed that nanozymes decreased the level of free radicals at low concentrations. In vitro and in vivo experiments revealed that the group treated with Fe-curcumin nanozymes had lower inflammatory reactions and ROS levels than the control group, as reflected by the downregulated levels of several critical inflammatory cytokines, such as IFN-γ, IL-17, and TNF-α; decreased H
conclusionThis study has demonstrated the feasibility of using the Fe-curcumin nanozyme as a nanodrug to inhibit inflammatory reactions and scavenge ROS in the treatment of EAU, indicating that it may serve as a promising therapeutic agent in clinical treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.